PROVIDES CONFIDENCE TO THE PHYSICIANS

By using CardioVia, physicians are able to work with great assurance knowing they have the ultimate device in their hands 

 

Providing safe and efficient access to the pericardial space

We at CardioVia are developing minimal invasive access to the outer surface of the heart via the pericardium which is a double-walled sac that surrounds the heart.

The outer surface of the heart has been recognized as a promising entry route for the treatment of the most prevalent cardiovascular diseases such as cardiac tamponade, mapping & ablation for various arrhythmias such as Atrial fibrillation and Ventricular tachycardia, left atrial appendage closure, epicardial lead placement and in the future, epicardial pacemaker implantation, drug, stem cells and gene therapy.

These devices and opportunities will unfold greatly once safely and reliably epicardial access will be achieved. It is estimated that, annually, 2.5M patients in the US and the EU will benefit from epicardial access due to a variety of pathological conditions.

​By using cutting edge technologies with the simplest ideas, CardioVia will be able to provide physicians with the right access to perform advanced cardiac treatments on the outer surface of the heart like never seen before. By using CardioVia, physicians will be able to perform procedures on one of the most delicate and complicated instruments that the human body has.

“The best way to predict your future is to create it.”

Abraham Lincoln
 
The Pericardium
The Problem

NOT SAFE - NOT EFFICIENT - NOT EASY

The Consequences

Minimally invasive, safe and efficient access to the pericardial space while generating a secure workspace

The Pericardium

The pericardium is a thin (only 2 mm) double-walled sac that surrounds the heart, protects and lubricates its motion. It composed of two layers, and in between these layers, there is a potential space called the pericardial space.

The

Problem

NOT SAFE - NOT EFFICIENT - NOT EASY

Penetration to the pericardial space carries a significant risk of damaging the heart as current procedures use a sharp needle that is directed towards the beating heart and fail to generate a secure work space.

The Consequences

Complications can reach up to 30% and include heart puncture, cardiac tamponade and pericardial bleeding, which can result in an increase in patient deaths. Quality of life will deteriorate and will result in additional treatments and healthcare costs.

Current Procedure

The pericardial tissue is very thin, ~2 mm thick

Current techniques lack sufficient monitoring and control

During the insertion, the heart is in constant motion

Requires agility, experience and great precision

 
Key Facts

CardioVia's device performs an accurate entrance between the layers of the pericardium thanks to cutting edge technologies while changing the way we think about the access. NO needle is exposed towards the heart.

The procedure is performed in a controlled and measured manner, while synchronizing with the heartbeats and the system allows penetration to the outer surface of the pericardial space without the risk of puncturing the heart muscle. 

While using a unique geometric structure tip, CardioVia's system utilizes the physiological differences between the pericardial tissue and the heart muscle itself. 

Once inserted, the device anchors to the pericardium and serves as a pathway that allows through it easy and secure continuous access.

Having An Edge
“Optimism is the faith that leads to achievement. Nothing can be done without hope and confidence."
Helen Keller
 

Some pictures from our latest venues, the ICI Meeting 2017, IDSS 2018 in Tel-Aviv and the ISMBE 2019 conference in Haifa. additionally we were invited to two technology conferences in China (Nanjing and Shnzhen) at 2019

logo 1.png
ISMBE LOGO.png

2019

Shenzhen - Israel  Technology Meeting 2019

China Israel Forum - Nanjing 2019

This project has received funding from the European Union’s Horizon 2020 research and innovation program under grant agreement No. 868213

“I am thankful for all of those who said NO to me.
It's because of them I'm doing it myself”
Albert Einstein
 

B.Sc Mechanical Engineering & M.Sc​ in Biomedical Engineering

R&D and Project management in the Medical Device industry

Ziv Menshes
CEO
  • Grey LinkedIn Icon

B.Sc & MBA from the Hebrew

University in Jerusalem Managerial and Financial experience

Biomed Development Management Diploma Israel Lean Launchpad - MERAGE INSTITUTE

Maor Rosenberg
CTO
  • Grey LinkedIn Icon
Or Hazan
COO
  • Grey LinkedIn Icon

LLM Masters in Business Law & LLB from the Hebrew University in Jerusalem experience in Business Law - & Finance specialization. Biomed Development Management Diploma Technion - Israel Institute of Technology

Nizar Mishael
CFO
  • Grey LinkedIn Icon

CPA & MBA, Managing Partner and CFO of NGT3VC. Acts as CFO for all portfolio companies certified CPA and holds an MBA from Tel Aviv University’s Recanati program.

Zohar Gendler
Chairman
  • Grey LinkedIn Icon

B.Sc & M.Sc, Former CEO and director of Beta-O2 technologies. Served as CEO of the Technion Entrepreneurial Incubator (TEIC) for a period of 11 years. Led the establishment and investment in Prolor Biotech (sold to Opko for $480M), Mazor (sold to Medtronic for $1.6B), Corindus (NASDAQ: CVRS) and many other companies.

Dr. Amir Toren
VP Bus. Dev.
  • Grey LinkedIn Icon

M.Sc, PhD, A published author, inventor and entrepreneurial CEO.

Prof. Michael Glikson
Medical Director
  • Grey LinkedIn Icon

Director of the Jesselson Integrated Heart Center of Shaare Zedek Medical Center in Jerusalem, in charge of both cardiology and cardiac surgery departments.

Since June 2015 he is the chair of the scientific program committee of European Heart Rhythm Association

Dr. Ran Eliaz
Medical Advisor  
  • Grey LinkedIn Icon

Cardiologist, Cardiology Department, Hadassah Ein Kerem Hospital

Dr. Yair Elitzur
Medical Advisor
  • Grey LinkedIn Icon

Electrophysiologist, Cardiology Department, Hadassah Ein Kerem Hospital

Dr. Yonatan Demma
Medical Advisor
  • Grey LinkedIn Icon

Surgeon, Hospital Saint Louis, APHP, Paris, France

 

 

There is a consensus that more and more cardiac treatments are moving towards a

minimal invasive epicardial approach instead of traditional endocardial catheterization

Ventricular Tachycardia

Ventricular tachycardia (VT) is a fast heart rhythm disorder that arises from improper electrical activity in the ventricles of the heart. When this happens, the heart may not be able to pump enough blood to the body and lungs because the chambers are beating so fast that they don't have enough time to fill properly.

VT is responsible for most of the sudden cardiac deaths in the United States, at an estimated rate of  300,000 deaths per year1,2.

The graph displays the increased rate of VT ablation procedures performed through the pericardium out of the total VT ablations that were performed in a multi-central study3.

The imaging on the left shows that in some cases the focus of the arrhythmia (marked in red) is presented on the surface of the heart (The right column). In this case, it is shown that there is a high relevance in accessing the pericardial space in order to perform ablation procedures for a more efficient treatment4.

1. Out-of-hospital cardiac arrest surveillance --- Cardiac Arrest Registry to Enhance Survival (CARES), United States, October 1, 2005--     December 31, 2010. MMWR Survival Summ. 2011 Jul 29. 60 (8):1-19. McNally B, Robb R, Mehta M, Valleano K, Valderrama AL, Yoon PW, et al.

2. Outcome of patients with in-hospital ventricular tachycardia and ventricular fibrillation arrest while using a wearable cardioverter defibrillator. Am J Cardiol. 2017 Nov 16. Ellenbogen KA, Wan C, Shavelle DM.

3. 15th Official Report of the Spanish Society of Cardiology Working Group on Electrophysiology and Arrhythmias, 2015

4. Epicardial Substrate and Outcome With Epicardial Ablation of Ventricular Tachycardia in Arrhythmogenic Right Ventricular Cardiomyopathy/Dysplasia. Fermin C. Garcia, Victor Bazan, Erica S. Zado, Jian-Fang Ren, Francis E. Marchlinski 

Atrial Fibrillation

Atrial fibrillation (A-Fib) is an irregular heart rate disorder that increases the risk for stroke, heart failure and other heart-related complications. During atrial fibrillation, the heart's two upper chambers beat out of coordination with the two lower chambers of the heart.

A-Fib is the most common serious abnormal heart arrhythmia. Billions of dollars are spent annually on its diagnosis and treatment (more than $6 Billion in the USA alone each year)1,2. With more than 750,000 hospitalizations that occur each year, A-Fib contributes to an estimated 130,000 deaths each year3,4.

This graph shows the results of recent studies that examined the efficiency of the hybrid approach. The superiority of the hybrid approach is particularly high in patients with persistent A-Fib which accounts for approx. 25% of A-Fib patients5.

1. January CT, Wann LS, Alpert JS, Calkins H, Cigarroa JE, Cleveland JC Jr, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. Journal of the American College of Cardiology. 2014;64(21):2246–80.

2. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015;131:e29–e322

3. Agency for Healthcare Research and Quality. Weighted national estimates. HCUP National Inpatient Sample [online]. 2012.

4. Centers for Disease Control and Prevention. About multiple cause of death 1999–2011. CDC WONDER Online Database. 2014.  

5. Zoni-Berisso M, Lercari F, Carazza T, Domenicucci S. Epidemiology of atrial fibrillation: European perspective. Clinical Epidemiology. 2014;6:213-220. doi:10.2147/CLEP.S47385.  

Drug Delivery

There are promising indications for the improvement of existing drugs by direct delivery to the epicardial space. This unique and specific area provides effective cardio active drug therapy without many of the side effects of conventional drug delivery methods.

 

This field aims to enhance outcomes of existing therapies by broadening their therapeutic window and to utilize new agents that otherwise could not be implemented systemically, such as gene and stem cells therapy. CardioVia will allow minimally invasive, safe and efficient agent delivery to the epicardial space.

1. "Delivery of drugs, growth factors, genes and stem cells via intrapericardial, epicardial and intramyocardial routes for sustained local targeted therapy of myocardial disease Mikhail Maslov, Stephan Foianini & Mark Lovich"

1

 

Stay in Touch

We want to hear from you!

|   ziv@cardiovia.com  |  or@cardiovia.com  |

  I   Tel-Aviv, Israel   I

EXPERIENCE TOMORROW TODAY

The Doorway To Advanced Cardiac Treatments

The people that form this company are the key to our success, they are our ambassadors and they are those who determine our reputation. CardioVia does not make any compromises regarding dignity and integrity, we treat all as equal.

Information regarding the company and its products under development is presented for general informational purposes only and is not intended to promote any product, state any specific product claims or imply that any product is safe or effective. Products discussed on this website may not be approved for use or available in all countries.

© 2019 by CardioVia Ltd. All rights reserved

Not approved for commercial distribution